CervoMed Inc. presented new data from the Phase 2b RewinD-LB trial demonstrating significant reductions in plasma GFAP and increased Ab42/40 ratio with neflamapimod treatment.
These results suggest broad improvements in neuroinflammation and neurodegeneration in patients with Dementia with Lewy Bodies (DLB).
The data presented at the 18th CTAD Conference confirms the potential of neflamapimod as a treatment for age-related brain disorders.
Reduction in Plasma GFAP
Significant reduction in the neurodegeneration biomarker plasma GFAP was observed with neflamapimod treatment.
Increase in Ab42/40 Ratio
Neflamapimod treatment led to an increase in the Ab42/40 ratio, indicating a positive impact on neuroinflammation and amyloidogenesis.
Trend in NfL Chain Levels
Neflamapimod treatment showed a trend towards reducing plasma neurofilament light (NfL) chains levels, further supporting its potential mechanism of action.
- The correlation between clinical benefit and plasma GFAP reduction validates GFAP as a biomarker of neurodegenerative disease activity in DLB.
- These findings strengthen confidence in neflamapimod's clinical effects and support the upcoming Phase 3 trial for DLB treatment.
The presented data underscores the potential of neflamapimod in improving neuroinflammation and neurodegeneration in DLB patients, offering hope for the development of effective treatments for this devastating disease.